Massimo Costantini

ORCID: 0000-0002-5293-7079
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Palliative Care and End-of-Life Issues
  • Cancer survivorship and care
  • Patient Dignity and Privacy
  • Childhood Cancer Survivors' Quality of Life
  • Patient-Provider Communication in Healthcare
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Family and Patient Care in Intensive Care Units
  • Geriatric Care and Nursing Homes
  • Long-Term Effects of COVID-19
  • Ethics in medical practice
  • Breast Cancer Treatment Studies
  • Grief, Bereavement, and Mental Health
  • Health Systems, Economic Evaluations, Quality of Life
  • Pain Management and Opioid Use
  • Gastroesophageal reflux and treatments
  • Family Support in Illness
  • Advances in Oncology and Radiotherapy
  • Breast Lesions and Carcinomas
  • Esophageal and GI Pathology
  • COVID-19 and healthcare impacts
  • Palliative and Oncologic Care
  • Frailty in Older Adults
  • Colorectal Cancer Surgical Treatments
  • Gastric Cancer Management and Outcomes

Istituti di Ricovero e Cura a Carattere Scientifico
2014-2025

Fondazione IRCCS Istituto Nazionale dei Tumori
2022-2024

Instituto Nazionale Tumori Regina Elena
2024

King's College London
2002-2024

Cicely Saunders International
2024

Azienda Sanitaria Unità Locale di Reggio Emilia
2018-2022

Collaborative Group (United States)
2022

Azienda Unità Sanitaria Locale Della Romagna
2019

Agostino Gemelli University Polyclinic
2019

Ospedale Santa Maria
2014-2017

The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies patients with COVID-19 pneumonia a good safety profile.To evaluate the effect early tocilizumab administration vs standard therapy preventing clinical worsening hospitalized pneumonia.Prospective, open-label, randomized trial that between March 31 and June 11, 2020, to receive or care 24 hospitals Italy. Cases were confirmed by...

10.1001/jamainternmed.2020.6615 article EN JAMA Internal Medicine 2020-10-20

Background: Palliative care is an important component of health in pandemics, contributing to symptom control, psychological support, and supporting triage complex decision making. Aim: To examine preparedness for, impact of, the COVID-19 pandemic on hospices Italy inform response other countries. Design: Cross-sectional telephone survey, March 2020. Setting: Italian hospices, purposively sampled according regional prevalence categorised as high (>25), medium (15–25) low (<15) cases...

10.1177/0269216320920780 article EN cc-by Palliative Medicine 2020-04-29

To describe actual and preferred place of death Italian cancer patients to analyse the preferences met regarding death.Mortality follow back survey 2000 deaths, identified with a two stage probability sample representative whole country. Information on patients' experience was gathered from non-professional caregiver an interview. A section interview covered information patients.30 local health districts randomly selected after stratification in four geographical areas.1900 (95.0%)...

10.1136/jech.2005.043646 article EN Journal of Epidemiology & Community Health 2006-04-13

10.1016/j.ejca.2008.02.024 article EN European Journal of Cancer 2008-03-15

The Hospital Anxiety and Depression Scale (HADS) is a widely used self-report measure to assess emotional distress in clinical populations. As highlighted recent review studies, the latent structure of HADS still an issue. aim this study was analyze factorial large community sample Italy, test invariance best fitting model across age gender groups. Data analyses were carried out on 1.599 participants proportionally stratified according Italian census population pyramid. Participants aged 18...

10.1186/1477-7525-12-84 article EN cc-by Health and Quality of Life Outcomes 2014-01-01
Francesco Perrone Maria Carmela Piccirillo Paolo A. Ascierto Carlo Salvarani Roberto Parrella and 95 more Anna Maria Marata Patrizia Popoli Laurenzia Ferraris Massimiliano M. Marrocco‐Trischitta Diego Ripamonti Francesca Binda Paolo Bonfanti Nicola Squillace Francesco Castelli María Lorenza Muiesan Miriam Lichtner Carlo Calzetti Nicola Duccio Salerno Luigi Atripaldi Marco Cascella Massimo Costantini Giovanni Dolci Nicola Facciolongo Fiorentino Fraganza Marco Massari Vincenzo Montesarchio Cristina Mussini Emanuele Alberto Negri Gerardo Botti Claudia Cardone Piera Gargiulo Adriano Gravina Clorinda Schettino Laura Arenare Paolo Chiodini Ciro Gallo Francesco Perrone Maria Carmela Piccirillo Clorinda Schettino Adriano Gravina Piera Gargiulo Claudia Cardone Laura Arenare Paolo A. Ascierto Maria Grazia Vitale Claudia Trojaniello Marco Palla Attilio Antonio Montano Bianchi Gerardo Botti Gianfranco De Feo Leonardo Miscio Ciro Gallo Paolo Chiodini Laurenzia Ferraris Massimiliano M. Marrocco‐Trischitta M. Froldi Lorenzo Menicanti Maria Teresa Cuppone Giulia Gobbo Chiara Baldessari Vincenzo Valenti Serenella Castelvecchio Federica Poli Francesca Giacomazzi Rosangela Piccinni Maria Laura Annnunziata Andrea Biondi Cecilia Bussolari Manuel Giovanni Mazzoleni Andrea Giachi Annalisa Filtz Arianna Manini Enrico Poletti Federico Masserini Francesco Conforti Gianfranco Gaudiano Vittoria Favero A. Moroni Tommaso Viva Fabiana Fancoli Davide Ferrari Dario Niro Marco Resta Andrea Ballotta Marco Poli Marco Ranucci Diego Ripamonti Francesca Binda Alessandra Tebaldi Giuseppe Gritti L. Pasulo Leonardo Gaglio Roberto Del Fabbro Leonardo Alborghetti Paolo Bonfanti Nicola Squillace Giulia Giustinetti Paola Columpsi Marina Elena Cazzaniga Serena Capici

Abstract Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis pneumonia the most frequent cause death COVID-19 patients. Methods A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, study effect tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, priori expected being 20 35%, respectively). further prospective cohort patients, consecutively enrolled after first accomplished,...

10.1186/s12967-020-02573-9 article EN cc-by Journal of Translational Medicine 2020-10-21

Rationale Pulse glucocorticoid therapy is used in hyperinflammation related to coronavirus disease 2019 (COVID-19). We evaluated the efficacy and safety of pulse intravenous methylprednisolone addition standard treatment COVID-19 pneumonia. Methods In this multicentre, randomised, double-blind, placebo-controlled trial, 304 hospitalised patients with pneumonia were randomised receive 1 g intravenously for three consecutive days or placebo dexamethasone. The primary outcome was duration...

10.1183/13993003.00025-2022 article EN cc-by-nc European Respiratory Journal 2022-03-31

This population-based study of all cancer deaths (n = 12,343) occurring in Genoa, Italy, from 1986 to 1990 investigated the relation between place death and age, sex, marital status, education, site provision palliative home care (PHC). The proportion significantly increased 27.9% (1986) 33.0% (1990) was twice as frequent among PHC users (60.8%) than nonusers (29.3%). number patients dying who received 41 (1.6% deaths) 191 (8.0% deaths). users, when compared were younger, more frequently...

10.1177/026921639300700410 article EN Palliative Medicine 1993-10-01

Although erythropoietin (EPO) is known to be useful in treating chemotherapy-induced anemia, few data are available on its potential preventive role. The aim of this study was evaluate the ability EPO preventing development clinically significant anemia patients treated with chemotherapy.Sixty-two early-stage breast cancer undergoing accelerated adjuvant chemotherapy were randomized receive 150 U/kg three times a week or no additional treatment. Chemotherapy consisted six cycles...

10.1200/jco.1997.15.7.2715 article EN Journal of Clinical Oncology 1997-07-01
Paolo Corradini Chiara Agrati Giovanni Apolone Alberto Mantovani Diana Giannarelli and 95 more Vincenzo Marasco Veronica Bordoni Alessandra Sacchi Giulia Matusali Carlo Salvarani Pier Luigi Zinzani Renato Mantegazza Fabrizio Tagliavini Maria Teresa Lupo Stanghellini Fabio Ciceri Silvia Damian Antonio Uccelli Daniela Fenoglio Nicola Silvestris Fausto Baldanti Giulia Piaggio Gennaro Ciliberto Aldo Morrone Franco Locatelli Valentina Sinno María Rescigno Massimo Costantini Giovanni Apolone Alberto Mantovani Massimo Costantini Nicola Silvestris Chiara Agrati Giovanni Apolone Fabio Ciceri Gennaro Ciliberto Massimo Costantini Franco Locatelli Alberto Mantovani Fausto Baldanti Aldo Morrone Angelo Paradiso Carlo Salvarani Nicola Silvestris Fabrizio Tagliavini Antonio Uccelli Pier Luigi Zinzani Paolo Corradini Gennaro Ciliberto Carlo Salvarani Antonio Uccelli Renato Mantegazza Chiara Agrati María Rescigno Daniela Fenoglio Roberta Mortarini Cristina Tresoldi Laura Conti Chiara Mandoj Michela Lizier Stefania Croci Fausto Baldanti Vito Michele Garrisi Fulvio Baggi Tiziana Lazzarotto Francesca Bonifazi Fulvia Pimpinelli Concetta Quintarelli Rita Carsetti Enrico Girardi Aurora Bettini Veronica Bordoni Concetta Castilletti Eleonora Cimini Rita Casetti Francesca Colavita Flavia Cristofanelli Massimo Francalancia Simona Gili Delia Goletti Giulia Gramigna Germana Grassi Daniele Lapa Sara Leone Davide Mariotti Giulia Matusali Silvia Meschi Stefania Notari Enzo Puro Marika Rubino Alessandra Sacchi Eleonora Tartaglia Paolo Corradini Silvia Damian Vincenzo Marasco Filippo de Braud Maria Teresa Lupo Stanghellini Lorenzo Dagna Francesca Rita Ogliari Massimo Filippi Alessandro Bruno

Abstract Background Patients with solid or hematological tumors neurological and immune-inflammatory disorders are potentially fragile subjects at increased risk of experiencing severe coronavirus disease 2019 an inadequate response to acute respiratory syndrome 2 (SARS-CoV-2) vaccination. Methods We designed a prospective Italian multicenter study assess humoral T-cell responses SARS-CoV-2 vaccination in patients (n = 378) (ST), malignancies (HM), (ND), immunorheumatological diseases (ID)....

10.1093/cid/ciac404 article EN cc-by-nc-nd Clinical Infectious Diseases 2022-05-24
Coming Soon ...